Highlights

  • Entropy Neurodynamics is developing TRP-8803, an intravenous psilocin formulation used alongside psychotherapy.
  • The infusion approach is designed to control dose delivery and the duration of a psychedelic session.
  • A 2026 company update reported a controlled response in the third participant in its binge-eating disorder study.
  • The company reported a 75% response rate in its Phase 2a oral psilocybin study involving treatment-resistant irritable bowel syndrome.
  • Clinical validation, patient safety and regulatory requirements remain central to further development.

Entropy Neurodynamics Limited (ASX:ENP) is a clinical-stage biotechnology company developing psilocin-based treatments administered alongside psychotherapy. Its lead program, TRP-8803, uses intravenous delivery to give clinicians more direct control over dosing than oral administration. The company’s 2026 disclosures address treatment delivery, early clinical findings and the requirements for evaluating the approach in larger patient groups.

Why Infusion Control Matters

Psilocin is the active metabolite of psilocybin. With oral psilocybin, absorption and conversion within the body can vary between patients. An intravenous infusion delivers psilocin directly into circulation, allowing clinicians to adjust the administration rate. Entropy Neurodynamics (ASX:ENP) is investigating whether this can make the onset, intensity and duration of the treatment experience more manageable in supervised settings.

TRP-8803 is not simply a different route for taking an established medicine. Its development requires evidence on tolerability, pharmacokinetics, treatment procedures and patient outcomes. The administration method is also relevant to clinic scheduling because prolonged treatment sessions require clinician supervision and follow-up care. Any operational advantages remain subject to clinical demonstration.

What 2026 Clinical Updates Establish

In an ASX announcement dated 14 April 2026, Entropy Neurodynamics (ASX:ENP) reported that its third participant in a binge-eating disorder study had completed two TRP-8803 infusions. The company said the participant experienced a controlled psychedelic response, providing evidence about administration under that study protocol. The finding concerns a small number of participants and does not establish therapeutic effectiveness across a wider population.

The company also reported results from an oral psilocybin program. Its 13 January 2026 announcement discussed a Phase 2a binge-eating disorder study, in which five patients were evaluable. The company reported a reduction in binge-eating episodes sustained through a 14-week follow-up. These findings relate to TRP-8802, rather than the intravenous TRP-8803 formulation, so their interpretation must remain separate.

In May 2026, Entropy Neurodynamics (ASX:ENP) announced a 75% response rate in a Phase 2a study of oral psilocybin for treatment-resistant irritable bowel syndrome. The reported results concerned a small clinical cohort and cannot by themselves demonstrate that intravenous delivery will produce equivalent outcomes. They provide therapeutic background for the company’s broader research program.

Development and Clinical Considerations

The distinction between controlling drug exposure and establishing a lasting clinical benefit remains important. Intravenous dosing may allow adjustment during a session, but treatment outcomes also depend on patient selection, supportive psychotherapy, monitoring and follow-up assessments. Entropy Neurodynamics (ASX:ENP) must evaluate these aspects as the TRP-8803 program progresses.

Research involving psychoactive compounds also requires appropriate clinical safeguards and regulatory oversight. Trial design, adverse-event reporting, reproducibility of results and the duration of observed effects are important factors in assessing the evidence. Commercial manufacturing and administration processes would involve further requirements beyond early-stage clinical testing.

Key Insights

Entropy Neurodynamics (ASX:ENP) is pursuing an infusion-based approach intended to make psilocin administration more controllable. Its 2026 updates provide early information about dosing and separately report findings from oral psilocybin studies. The central distinction is between delivery feasibility and clinical efficacy: the former does not establish the latter. Further evidence will determine how the technology can be evaluated in larger, controlled settings.